{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CLYYF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYYF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYYF\",,,,,undefined,":{"symbol":"CLYYF","market":"US","secType":"STK","nameCN":"Celyad Oncology SA","latestPrice":0.5,"timestamp":1751562000000,"preClose":0.5,"halted":0,"volume":0,"delay":15,"floatShares":14140089,"shares":41428572,"eps":-0.145542,"marketStatus":"Closed Independence Day","change":0,"latestTime":"07-03 13:00:00 EDT Delay","open":0.5,"high":0.5,"low":0.5,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.145542,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.5,"volumeRatio":3.678618498167212},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYYF\",,,,,undefined,":{"symbol":"CLYYF","floatShares":14140089,"roa":"-27.99%","roe":"-170.92%","lyrEps":-0.145542,"volumeRatio":3.678618498167212,"shares":41428572,"dividePrice":0,"high":0.5,"amplitude":0,"preClose":0.5,"low":0.5,"week52Low":0.245,"pbRate":"34.42","psRate":"94.55","week52High":0.68,"institutionHeld":0,"latestPrice":0.5,"eps":-0.145542,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.145542,"open":0.5,"prevYearClose":0.245,"prevWeekClose":0.5,"prevMonthClose":0.5,"prevQuarterClose":0.5,"fiveDayClose":0.5,"twentyDayClose":0.5,"sixtyDayClose":0.65},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CLYYF\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLYYF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512181635","title":"Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2512181635","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512181635?lang=en_us&edition=fundamental","pubTime":"2025-02-18 14:00","pubTimestamp":1739858400,"startTime":"0","endTime":"0","summary":"Celyad Oncology     , today announces the publication of the preclinical data of the non-gene edited allogeneic CYAD-211 and clinical data from the Phase I IMMUNICY-1 clinical study which evaluated CYAD-211 in relapsed or refractory (r/r) multiple myeloma  patients. The findings were published in the International Journal of Molecular Science .CYAD-211 is the Company’s first allogeneic chimeric antigen receptor  T-cell candidate, engineered to co-express a B-cell maturation antigen -specific CAR and a microRNA-based single shRNA which interferes with the expression of the CD3ζ component of the T-cell receptor  complex, evaluated clinically.Overall, these data provides the proof-of-concept of the safe administration of CAR T-cells engineered using a miRNA-based shRNA technology. CYAD-211 is the first allogeneic CAR T-cell candidate using a non-gene edited approach to achieve allogenicity. This differentiated strategy provides key advantages by being easily implemented, safe, efficient, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celyad-oncology-announces-publication-preclinical-060000980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAR","CLYYF","BK4230","BK4022","CYAD","BK4139"],"gpt_icon":0},{"id":"2473887724","title":"Celyad Oncology to Present at the 2024 SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2473887724","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473887724?lang=en_us&edition=fundamental","pubTime":"2024-10-08 00:00","pubTimestamp":1728316800,"startTime":"0","endTime":"0","summary":"Celyad Oncology  , today announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer , being held in Houston, November 6-10, 2024.This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company’s updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company’s IP, and statements regarding the continuation of the Company’s existence. The words \"will,\" \"potential,\" \"continue,\" \"target,\" \"project,\" \"should\" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management’s current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which mi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dJH9qdUkXumVeXVrC138ng--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8f69f1af99d660018ac49d8e26fd8fcd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dJH9qdUkXumVeXVrC138ng--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8f69f1af99d660018ac49d8e26fd8fcd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celyad-oncology-present-2024-sitc-160000722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4139","CLYYF","BK4230","BK4022","CAR","BK4080","SITC"],"gpt_icon":0},{"id":"2468807847","title":"Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2468807847","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468807847?lang=en_us&edition=fundamental","pubTime":"2024-09-17 00:00","pubTimestamp":1726502400,"startTime":"0","endTime":"0","summary":"Celyad Oncology   is pleased to announce Matt Kane as its new Chief Executive Officer , effective as of October 1st, 2024.Matt Kane is a seasoned executive with over 20 years of experience in entrepreneurial, CEO and board roles. Mr. Kane is a pioneer in genome editing, led the development of the first editing technology to receive clearance for clinical evaluation as an in vivo gene insertion therapeutic and, most importantly, led the development and clinical testing of multiple allogeneic chimeric antigen receptor  T-cell therapies directed against cancer. His extensive scientific and business acumen have been demonstrated during his career by raising over $500M in equity financings and partnerships valued at over $4B.Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/P_BviJ_1OYtYmfGZv57HzA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e4af18dd508918d7b650a392a97cb49f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/P_BviJ_1OYtYmfGZv57HzA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e4af18dd508918d7b650a392a97cb49f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celyad-oncology-announces-appointment-matt-160000777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAR","CEO","DTIL","BK4022","CLYYF","BK4230","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYYF\",params:#limit:5,,,undefined,":[{"date":"2022-11-10","symbol":"CLYYF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668070800000,"name":null,"time":"","dateTimestamp":1668056400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYYF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYYF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1751601600000}}}